Starpharma Holdings Limited (FRA:PQ6)

Germany flag Germany · Delayed Price · Currency is EUR
0.210
+0.020 (10.53%)
Last updated: Dec 5, 2025, 8:06 AM CET
247.11%
Market Cap 94.17M
Revenue (ttm) 3.27M
Net Income (ttm) -5.58M
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 1,115
Open 0.210
Previous Close 0.190
Day's Range 0.210 - 0.210
52-Week Range 0.031 - 0.238
Beta n/a
RSI 55.73
Earnings Date Nov 24, 2025

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 40
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PQ6
Full Company Profile

Financial Performance

In 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.